Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2006 1
2007 10
2008 8
2009 1
2010 9
2011 14
2012 9
2013 6
2014 2
2015 5
2016 5
2017 5
2018 1
2019 5
2020 3
2021 7
2022 5
2023 3
2024 4
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean examorelin (3 results)?
Tesamorelin.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644039 Free Books & Documents. Review.
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipi …
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodefic …
Tesamorelin.
Grunfeld C, Dritselis A, Kirkpatrick P. Grunfeld C, et al. Nat Rev Drug Discov. 2011 Feb;10(2):95-6. doi: 10.1038/nrd3362. Nat Rev Drug Discov. 2011. PMID: 21283099
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy....
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by th …
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Fourman LT, et al. JCI Insight. 2020 Aug 20;5(16):e140134. doi: 10.1172/jci.insight.140134. JCI Insight. 2020. PMID: 32701508 Free PMC article. Clinical Trial.
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. ...
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, am …
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
Dhillon S. Dhillon S. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Drugs. 2011. PMID: 21668043 Review.
Tesamorelin (Egrifta) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. ...Tesamorelin was generally well tolerated, with treatmen …
Tesamorelin (Egrifta) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing facto …
Tesamorelin, a human growth hormone releasing factor analogue.
Wang Y, Tomlinson B. Wang Y, et al. Expert Opin Investig Drugs. 2009 Mar;18(3):303-10. doi: 10.1517/13543780802707658. Expert Opin Investig Drugs. 2009. PMID: 19243281 Review.
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications. ...Other potential indications for tesamorelin appear less promising from the current data....
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potentia …
Clinical Review Report: Tesamorelin (Egrifta).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. PMID: 30920787 Free Books & Documents. Review.
Excess VAT negatively affects patients' body image and quality of life (QoL). Tesamorelin is a synthetic analogue of growth hormone-releasing factor that triggers diverse metabolic effects, including lipolysis. The objective of this systematic review was to evaluate the be …
Excess VAT negatively affects patients' body image and quality of life (QoL). Tesamorelin is a synthetic analogue of growth hormone-r …
Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Lake JE, et al. AIDS. 2021 Jul 15;35(9):1395-1402. doi: 10.1097/QAD.0000000000002897. AIDS. 2021. PMID: 33756511 Free PMC article.
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 ( …
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -9 …
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.
Fourman LT, Stanley TL, Billingsley JM, Sui SJH, Feldpausch MN, Boutin A, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK. Fourman LT, et al. Sci Rep. 2021 May 18;11(1):10485. doi: 10.1038/s41598-021-89966-y. Sci Rep. 2021. PMID: 34006921 Free PMC article.
We further showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division. ...Among tesamorelin-treated participants, reductions in plasma VEGFA (r = 0.62, P = 0.006) and CSF1 (r = 0.50, P = 0.04) correlated with a …
We further showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division. ...Amo …
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Rahman F, et al. J Clin Transl Sci. 2022 Dec 7;7(1):e40. doi: 10.1017/cts.2022.515. eCollection 2023. J Clin Transl Sci. 2022. PMID: 36845310 Free PMC article.
Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Ef …
Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people …
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, Stanley TL, Hadigan CM, Grinspoon SK, Erlandson KM, Fourman LT. Russo SC, et al. AIDS. 2024 Oct 1;38(12):1758-1764. doi: 10.1097/QAD.0000000000003965. Epub 2024 Jun 20. AIDS. 2024. PMID: 38905488 Free PMC article. Clinical Trial.
OBJECTIVE: Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). ...Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups. ...
OBJECTIVE: Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). ...Tesamorel …
110 results